Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Anemia
Iron Deficiency Anemia
About this trial
This is an interventional treatment trial for Iron Deficiency Anemia focused on measuring Anemia in pregnancy, Lactoferrin, Iron Sucrose
Eligibility Criteria
Inclusion Criteria: Pregnant women with iron deficiency anemia. Microcytic hypochromic anemia, moderate anemia (Hb 8 to 9.9 g/dl) and S. Ferritin levels <12 ng/dl as per WHO guidelines Gestational age: - 13-26 weeks. Singleton viable pregnancy Lastly, agreement to participate and sign the informed consent was a basic prerequisite Exclusion Criteria:- Women with a history of anemia due to any other causes such as chronic blood loss, hemolytic anemia, and thalassemia (including thalassemia trait). Severe anemia <7 g/dl requiring blood transfusion, bronchial asthma, clinical and/or laboratory evidence of hepatic, renal, hematologic or cardiovascular abnormalities. History of peptic ulcer. Hypersensitivity to iron preparations and treatment with any other iron preparation in the last one month before study entry. Suspected acute infection.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Intravenous Iron Sucrose group
Lactoferrin group
50 pregnant women will receive 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose -The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\dL - actual Hb in g\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg
50 pregnant women will receive lactoferrin 100 twice daily orally .